Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with
sorafenib is safe for patients with metastatic renal cell carcinoma (RCC).